Kepos Capital LP Bristol Myers Squibb CO Transaction History

Kepos Capital LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$57.89 - $64.73 $5,557 - $6,214	96 Added 17.61%	641 $37,000
Q2 2023 Aug 10, 2023	BUY	$63.71 - $70.74 $2,166 - $2,405	34 Added 6.65%	545 $35,000
Q4 2022 Feb 13, 2023	BUY	$68.48 - $81.09 $34,993 - $41,436	511 New	511 $37,000
Q3 2019 Nov 13, 2019	SELL	$42.77 - $50.71 $2.38 Million - $2.82 Million	-55,654 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$44.62 - $49.34 $3.15 Million - $3.49 Million	-70,688 Reduced 55.95%	55,654 $2.52 Million
Q1 2019 May 13, 2019	SELL	$45.12 - $53.8 $238,729 - $284,655	-5,291 Reduced 4.02%	126,342 $6.03 Million
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $6.42 Million - $8.32 Million	131,633 New	131,633 $6.84 Million
Q2 2018 Aug 13, 2018	SELL	$50.53 - $62.98 $1.06 Million - $1.32 Million	-20,972 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$59.92 - $68.98 $927,801 - $1.07 Million	-15,484 Reduced 42.47%	20,972 $1.33 Million
Q4 2017 Feb 12, 2018	BUY	$59.94 - $65.35 $2.19 Million - $2.38 Million	36,456	36,456 $2.23 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Kepos Capital LP, based on Form 13F filings with the SEC.

Stay updated on Kepos Capital LP with notifications on news.